It was reported on Thursday that United States-based BioMarin has named Maykin Ho, PhD, as its new director.
Dr Ho has over 30 years of experience in the healthcare and finance industries. She is serving on the boards of Agios Pharmaceuticals Inc, FibroGen Inc, Grail Inc, Parexel, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. She is a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She has served in Goldman Sachs Group, DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.
Jean-Jacques Bienaime, chairman and CEO at BioMarin, said, 'We are thrilled to welcome Maykin to BioMarin's board of directors. She brings a breadth and depth of experience in the healthcare industry and finance to an already exceptional board. Maykin brings an important perspective to support BioMarin's growth trajectory as we strive to address the unmet medical needs of people affected by rare genetic diseases and deliver scientific breakthroughs.'
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study